Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?

References

• Abboud M, Laver J, Blau CA. Granulocytosis causing sickle-cell crisis. Lancet. 1998; 351(9107)959
   PubMed Web of Science ®Google Scholar
• Adler BK, Salzman DE, Carabasi MH, Vaughan WP, Reddy VV, Prchal JT. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood. 2001; 97(10)3313–4
   PubMed Web of Science ®Google Scholar
• Grigg AP. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta + thalassemia. Blood. 2001; 97(12)3998–9
   Google Scholar
• Kamble RT, Tin UC, Carrum G. Successful mobilization and transplantation of filgrastim mobilized hematopoietic stem cells in sickle cell-hemoglobin C disease. Bone Marrow Transplant. 2006; 37(11)1065–6
   Google Scholar
• Rosenbaum C, Peace D, Rich E, Van Besien K. Granulocyte colony-stimulating factor-based stem cell mobilization in patients with sickle cell disease. Biol Blood Marrow Transplant. 2008; 14(6)719–23
   Google Scholar
• Onitilo AA, Lazarchick J, Brunson CY, Frei-Lahr D, Stuart RK. Autologous bone marrow transplant in a patient with sickle cell disease and diffuse large B-cell lymphoma. Transplant Proc. 2003; 35(8)3089–92
   Google Scholar
• Tormey CA, Snyder EL, Cooper DL. Mobilization, collection, and transplantation of peripheral blood hematopoietic progenitor cells in a patient with multiple myeloma and hemoglobin SC disease. Transfusion 2008; 48(9)1930–33
   Google Scholar
• Dallalio G, Brunson CY, Means RT, Jr. Cytokine concentrations in bone marrow of stable sickle cell anemia patients. J Invest Med. 2007; 55(2)69–74
   Google Scholar
• Akohoue SA, Shankar S, Milne GL, Morrow J, Chen KY, Ajayi WU, et al. Energy expenditure, inflammation, and oxidative stress in steady-state adolescents with sickle cell anemia. Pediatric Res. 2007; 61(2)233–8
   Google Scholar
• Lee SP, Ataga KI, Orringer EP, Phillips DR, Parise LV. Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arteriosclerosis, thrombosis, and vascular biology. 2006; 26(7)1626–31
   PubMed Web of Science ®Google Scholar
• Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. New Engl J Med. 1994; 330(23)1639–44
   PubMed Web of Science ®Google Scholar
• Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, et al. Prediction of adverse outcomes in children with sickle cell disease. New Engl J Med. 2000; 342(2)83–9
   PubMed Web of Science ®Google Scholar
• Quinn CT, Lee NJ, Shull EP, Ahmad N, Rogers ZR, Buchanan GR. Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn Cohort. Blood. 2008; 111(2)544–8
   Google Scholar
• Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. New Engl J Med. 1995; 332(20)1317–22
   PubMed Web of Science ®Google Scholar
• Saleh AW, Hillen HF, Duits AJ. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol. 1999; 102(1)31–7
   Google Scholar
• Miller MK, Zimmerman SA, Schultz WH, Ware RE. Hydroxyurea therapy for pediatric patients with hemoglobin SC disease. J Pediatr Hematol Oncol. 2001; 23(5)306–8
   Google Scholar
• Abboud MR, Taylor EC, Habib D, Dantzler-Johnson T, Jackson SM, Xu F, et al. Elevated serum and bronchoalveolar lavage fluid levels of interleukin 8 and granulocyte colony-stimulating factor associated with the acute chest syndrome in patients with sickle cell disease. Br J Haematol. 2000; 111(2)482–90
   PubMed Web of Science ®Google Scholar
• Conran N, Almeida CB, Lanaro C, Ferreira RP, Traina F, Saad ST, et al. Inhibition of caspase-dependent spontaneous apoptosis via a cAMP-protein kinase A dependent pathway in neutrophils from sickle cell disease patients. Br J Haematol. 2007; 139(1)148–58
   PubMed Web of Science ®Google Scholar
• Hofstra TC, Kalra VK, Meiselman HJ, Coates TD. Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst. Blood. 1996; 87(10)4440–7
   PubMed Web of Science ®Google Scholar
• Fadlon E, Vordermeier S, Pearson TC, Mire-Sluis AR, Dumonde DC, Phillips J, et al. Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood. 1998; 91(1)266–74
   PubMed Web of Science ®Google Scholar
• Stroncek DF, Jaszcz W, Herr GP, Clay ME, McCullough J. Expression of neutrophil antigens after 10 days of granulocyte-colony-stimulating factor. Transfusion. 1998; 38(7)663–8
   Google Scholar
• Assis A, Conran N, Canalli AA, Lorand-Metze I, Saad ST, Costa FF. Effect of cytokines and chemokines on sickle neutrophil adhesion to fibronectin. Acta Haematol. 2005; 113(2)130–6
   PubMedGoogle Scholar
• Lichtman MA, Miller DR, Cohen J, Waterhouse C. Reduced red cell glycolysis, 2, 3-diphosphoglycerate and adenosine triphosphate concentration, and increased hemoglobin-oxygen affinity caused by hypophosphatemia. Ann Intern Med. 1971; 74(4)562–8
   Google Scholar
• Russell MO, Goldberg HI, Hodson A, Kim HC, Halus J, Reivich M, et al. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood. 1984; 63(1)162–9
   PubMed Web of Science ®Google Scholar
• Pegelow CH, Adams RJ, McKie V, Abboud M, Berman B, Miller ST, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatrics. 1995; 126(6)896–9
   PubMed Web of Science ®Google Scholar
• Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. New Engl J Med. 1998; 339(1)5–11
   PubMed Web of Science ®Google Scholar
• Kang EM, Areman EM, David-Ocampo V, Fitzhugh C, Link ME, Read EJ, et al. Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood. 2002; 99(3)850–5
   Google Scholar
• Sunshine HR, Hofrichter J, Eaton WA. Gelation of sickle cell hemoglobin in mixtures with normal adult and fetal hemoglobins. J Mol Biol. 1979; 133(4)435–67
   Google Scholar
• Abboud, MR, Dover, GJ, Jackson, S, Brunson, CY, Forcier, A, Oette, D, , et al. A Pilot Study of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor and Hydroxyurea in Patients with Sickle Cell Disease. New York: The National Sickle Cell Disease Program; 1994. abstract.
   Google Scholar
• Bronchud MH, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer. 1987; 56(6)809–13
   PubMedGoogle Scholar
• Gabrilove JL, Jakubowski A, Fain K, Grous J, Scher H, Sternberg C, et al. Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest. 1988; 82(4)1454–61
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. New Engl J Med. 1988; 318(22)1414–22
   PubMed Web of Science ®Google Scholar
• Morstyn G, Campbell L, Souza LM, Alton NK, Keech J, Green M, et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet. 1988; 1(8587)667–72
   PubMed Web of Science ®Google Scholar
• Bronchud MH, Howell A, Crowther D, Hopwood P, Souza L, Dexter TM. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer. 1989; 60(1)121–5
   Google Scholar
• Neidhart J, Mangalik A, Kohler W, Stidley C, Saiki J, Duncan P, et al. Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation. J Clin Oncol. 1989; 7(11)1685–92
   PubMed Web of Science ®Google Scholar
• Dale DC, Bonilla MA, Davis MW, Nakanishi AM, Hammond WP, Kurtzberg J, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood. 1993; 81(10)2496–502
   PubMed Web of Science ®Google Scholar
• Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. International Acute Myeloid Leukemia Study Group. Blood. 1997; 90(12)4710–8
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007; 25(21)3158–67
   PubMed Web of Science ®Google Scholar
• Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005; 23(18)4198–214
   PubMed Web of Science ®Google Scholar
• Amgen, I. Neupogen® Prescribing Information. http://www.neupogen.com/pi.html; September, 2007. Accessed 22 September 2008.
   Google Scholar
• Irfan M, Hashmi K, Adil S, Shamsi T, Farzana T, Ansari S, et al. Beta-thalassaemia major: bone marrow versus peripheral blood stem cell transplantation. JPMA. 2008; 58(3)107–10
   Google Scholar
• Meisel R, Laws HJ, Balzer S, Bernbeck B, Kramm C, Schonberger S, et al. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies. Biol Blood Marrow Transplant. 2007; 13(11)1338–45
   Google Scholar
• Remberger M, Ringden O. Similar outcome after unrelated allogeneic peripheral blood stem cell transplantation compared with bone marrow in children and adolescents. Transplantation. 2007; 84(4)551–4
   Google Scholar
• Schmitz N, Eapen M, Horowitz MM, Zhang MJ, Klein JP, Rizzo JD, et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood. 2006; 108(13)4288–90
   PubMed Web of Science ®Google Scholar
• Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007; 110(4)1397–400
   PubMed Web of Science ®Google Scholar
• Dey BR, Shaffer J, Yee AJ, McAfee S, Caron M, Power K, et al. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. Bone Marrow Transplant. 2007; 40(1)19–27
   Google Scholar
• Benboubker L, Cartron G, Roingeard F, Delain M, Degenne M, Linassier C, et al. Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow. Exp Hematol. 2003; 31(1)89–97
   Google Scholar
• Hematti P, Tuchman S, Larochelle A, Metzger ME, Donahue RE, Tisdale JF. Comparison of retroviral transduction efficiency in CD34 + cells derived from bone marrow versus G-CSF-mobilized or G-CSF plus stem cell factor-mobilized peripheral blood in nonhuman primates. Stem Cells. 2004; 22(6)1062–9
   Google Scholar
• Vichinsky EP, Haberkern CM, Neumayr L, Earles AN, Black D, Koshy M, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. New Engl J Med. 1995; 333(4)206–13
   PubMed Web of Science ®Google Scholar
• Neumayr L, Koshy M, Haberkern C, Earles AN, Bellevue R, Hassell K, et al. Surgery in patients with hemoglobin SC disease. Preoperative Transfusion in Sickle Cell Disease Study Group. Am J Hematol. 1998; 57(2)101–8
   Google Scholar
• de Vries EG, Vriesendorp R, Meinesz AF, Mulder NH, Postmus PE, Sleijfer DT. No narcosis for bone marrow harvest in autologous bone marrow transplantation. Blut 1984; 49(5)419–21
   Google Scholar
• Dicke KA, Hood DL, Hanks S, Vaughan M, Fulbright L, Dicke JA, et al. A marrow harvest procedure under local anesthesia. Exp Hematol. 1995; 23(11)1229–32
   Google Scholar
• Karlsson L, Quinlan D, Guo D, Brown C, Selinger S, Klassen J, et al. Mobilized blood cells vs bone marrow harvest: experience compared in 171 donors with particular reference to pain and fatigue. Bone Marrow Transplant. 2004; 33(7)709–13
   Google Scholar
• Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr. 2004; 37(2)1253–62
   PubMed Web of Science ®Google Scholar
• Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003; 102(8)2728–30
   PubMed Web of Science ®Google Scholar